148 related articles for article (PubMed ID: 31259731)
1. Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
Ajani OO; Nlebemuo MT; Adekoya JA; Ogunniran KO; Siyanbola TO; Ajanaku CO
Acta Pharm; 2019 Jun; 69(2):177-196. PubMed ID: 31259731
[TBL] [Abstract][Full Text] [Related]
2. Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents.
Montero V; Montana M; Carré M; Vanelle P
Eur J Med Chem; 2024 May; 271():116360. PubMed ID: 38614060
[TBL] [Abstract][Full Text] [Related]
3. Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery.
Pinheiro AC; Mendonça Nogueira TC; de Souza MV
Anticancer Agents Med Chem; 2016; 16(10):1339-52. PubMed ID: 27349448
[TBL] [Abstract][Full Text] [Related]
4. An insight into medicinal chemistry of anticancer quinoxalines.
Kaushal T; Srivastava G; Sharma A; Singh Negi A
Bioorg Med Chem; 2019 Jan; 27(1):16-35. PubMed ID: 30502116
[TBL] [Abstract][Full Text] [Related]
5. Present status of quinoxaline motifs: excellent pathfinders in therapeutic medicine.
Ajani OO
Eur J Med Chem; 2014 Oct; 85():688-715. PubMed ID: 25128670
[TBL] [Abstract][Full Text] [Related]
6. Quinoxaline: An insight into the recent pharmacological advances.
Tariq S; Somakala K; Amir M
Eur J Med Chem; 2018 Jan; 143():542-557. PubMed ID: 29207337
[TBL] [Abstract][Full Text] [Related]
7. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of New Quinoxaline Derivatives as Anticancer Agents and Apoptotic Inducers.
El Newahie AMS; Nissan YM; Ismail NSM; Abou El Ella DA; Khojah SM; Abouzid KAM
Molecules; 2019 Mar; 24(6):. PubMed ID: 30934622
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of in vitro antiproliferative activity of new ethyl 3-(arylethynyl)quinoxaline-2-carboxylate and pyrido[4,3-b]quinoxalin-1(2H)-one derivatives.
Hajri M; Esteve MA; Khoumeri O; Abderrahim R; Terme T; Montana M; Vanelle P
Eur J Med Chem; 2016 Nov; 124():959-966. PubMed ID: 27770736
[TBL] [Abstract][Full Text] [Related]
12. Discovery of indeno[1,2-b]quinoxaline derivatives as potential anticancer agents.
Tseng CH; Chen YR; Tzeng CC; Liu W; Chou CK; Chiu CC; Chen YL
Eur J Med Chem; 2016 Jan; 108():258-273. PubMed ID: 26686931
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral activity of quinoxaline derivatives: A systematic review.
Montana M; Mathias F; Terme T; Vanelle P
Eur J Med Chem; 2019 Feb; 163():136-147. PubMed ID: 30503938
[TBL] [Abstract][Full Text] [Related]
14. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
Feng LS; Gao C; Liu FW; Wang XP; Zhang ZL
Curr Top Med Chem; 2022; 22(17):1426-1441. PubMed ID: 36028933
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Wang T; Tang Y; Yang Y; An Q; Sang Z; Yang T; Liu P; Zhang T; Deng Y; Luo Y
Bioorg Med Chem Lett; 2018 Jun; 28(11):2084-2090. PubMed ID: 29748048
[TBL] [Abstract][Full Text] [Related]
16. [1,2,4]triazolo[4,3-
Patinote C; Raevens S; Baumann A; Pellegrin E; Bonnet PA; Deleuze-Masquéfa C
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513350
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
18. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity.
Grande F; Aiello F; Garofalo A; Neamati N
Mini Rev Med Chem; 2016; 16(8):644-50. PubMed ID: 26955877
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era.
Yadav S; Narasimhan B; Kaur H
Anticancer Agents Med Chem; 2016; 16(11):1403-1425. PubMed ID: 26526461
[TBL] [Abstract][Full Text] [Related]
20. Quinoxaline chemistry. Part 13: 3-Carboxy-2-benzylamino-substituted quinoxalines and N-[4-[(3-carboxyquinoxalin-2-yl) aminomethyl]benzoyl]-L-glutamates: synthesis and evaluation of in vitro anticancer activity.
Corona P; Vitale G; Loriga M; Paglietti G
Farmaco; 2000 Feb; 55(2):77-86. PubMed ID: 10782376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
